Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 103 articles:
HTML format



Single Articles


    January 2022
  1. MAZAKI AI, Yamauchi K, Orita S, Inage K, et al
    Nerve Growth Factor in Breast Cancer Cells Promotes Axonal Growth and Expression of Calcitonin Gene-related Peptide in a Rat Model of Spinal Metastasis.
    Anticancer Res. 2022;42:581-587.
    PubMed     Abstract available


  2. HENRIQUES PALMA GB, Kaur M
    Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen.
    Anticancer Res. 2022;42:565-579.
    PubMed     Abstract available


  3. HOSOYA K, Nosaka K, Sakabe T, Wakahara M, et al
    Clinical Significance of Serglycin Expression in Human Breast Cancer Patients.
    Anticancer Res. 2022;42:279-285.
    PubMed     Abstract available


  4. MEIROVITZ A, Nisman B, Allweis TM, Carmon E, et al
    Thyroid Hormones and Morphological Features of Primary Breast Cancer.
    Anticancer Res. 2022;42:253-261.
    PubMed     Abstract available


  5. ASANO Y, Kashiwagi S, Takada K, Ishihara S, et al
    Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer.
    Anticancer Res. 2022;42:125-136.
    PubMed     Abstract available


  6. SAYAN M, Vergalasova I, Jan I, Kumar S, et al
    Toxicities and Locoregional Control After External Beam Chest Wall and/or Regional Lymph Node Re-irradiation for Recurrent Breast Cancer.
    Anticancer Res. 2022;42:93-96.
    PubMed     Abstract available


  7. SAYAN M, Yehia ZA, Jan I, Gupta A, et al
    Adaptive Lumpectomy Boost Planning Can Reduce Normal Tissue Exposure in Patients Receiving Hypofractionated Whole Breast Irradiation.
    Anticancer Res. 2022;42:53-57.
    PubMed     Abstract available


  8. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    The Effect of Smoking on Progression from Ductal Carcinoma In Situ to Invasive Ductal Breast Carcinoma: A Retrospective Study.
    Anticancer Res. 2022;42:311-320.
    PubMed     Abstract available


    December 2021
  9. MAMISHIN K, Naito Y, Nomura S, Ogawa G, et al
    Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2021;41:6217-6224.
    PubMed     Abstract available


  10. HONG SE, Jin HO, Kim SM, Jang SK, et al
    miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor.
    Anticancer Res. 2021;41:6169-6176.
    PubMed     Abstract available


  11. MOTOMURA H, Tamori S, Yatani MA, Namiki A, et al
    GLO 1 and PKClambda Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
    Anticancer Res. 2021;41:5959-5971.
    PubMed     Abstract available


  12. ACUNA UM, Ezzone N, Rakotondraibe LH, Carcache DE Blanco EJ, et al
    Activity in MCF-7 Estrogen-sensitive Breast Cancer Cells of Capsicodendrin from Cinnamosma fragrans.
    Anticancer Res. 2021;41:5935-5944.
    PubMed     Abstract available


  13. KANGA KJW, Mendonca P, Soliman KFA, Ferguson DT, et al
    Effect of Diallyl Trisulfide on TNF-alpha-induced CCL2/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2021;41:5919-5933.
    PubMed     Abstract available


  14. NOMURA T, Kurebayashi J, Moriya T, Saito W, et al
    A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
    Anticancer Res. 2021;41:6191-6197.
    PubMed     Abstract available


  15. COLLERY P, Veena V, Desmaele D, Harikrishnan A, et al
    Effects of Rhenium(I)-diselenoether and of its Diselenide Ligand on the Production of Cathepsins B and S by MDA-MB231 Breast Malignant Cells.
    Anticancer Res. 2021;41:5997-6001.
    PubMed     Abstract available


    November 2021
  16. TOKISAWA H, Aruga T, Honda Y, Ishiba T, et al
    Safety and Effectiveness of Areola-sparing Mastectomy for Breast Cancer With Intraductal Lesions.
    Anticancer Res. 2021;41:5723-5728.
    PubMed     Abstract available


  17. PIANKA J, Gruba N, Kitowska K, Mieczkowski K, et al
    Simplified Theta-defensin [Ser(3,7,12,16)] RTD-2 Analog Is Involved in Proteasomal Degradation Pathway in Breast Cancer.
    Anticancer Res. 2021;41:5415-5423.
    PubMed     Abstract available


  18. VANNI G, Caiazza G, Materazzo M, Storti G, et al
    Erector Spinae Plane Block Versus Serratus Plane Block in Breast Conserving Surgery: Alpha Randomized Controlled Trial.
    Anticancer Res. 2021;41:5667-5676.
    PubMed     Abstract available


  19. VANNI G, Pellicciaro M, Sadri A, Tacconi F, et al
    Pre-pectoral Breast Reconstruction Does Not Affect Early Immunological Response: A BIAL 2.20 Study Subanalysis.
    Anticancer Res. 2021;41:5657-5665.
    PubMed     Abstract available


    October 2021
  20. FRIEDRICH RE, Madani E
    Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer.
    Anticancer Res. 2021;41:5081-5087.
    PubMed     Abstract available


  21. VAHAAHO N, Hakamies-Blomqvist L, Blomqvist C, Kellokumpu-Lehtinen PL, et al
    Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients.
    Anticancer Res. 2021;41:5045-5052.
    PubMed     Abstract available


  22. TAKASHIMA T, Nishimura S, Kawajiri H, Mizuyama Y, et al
    An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
    Anticancer Res. 2021;41:5007-5014.
    PubMed     Abstract available


  23. WU NF, Yamamoto J, Aoki Y, Masaki N, et al
    The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Anticancer Res. 2021;41:4715-4718.
    PubMed     Abstract available


    September 2021
  24. VANNI G, Pellicciaro M, Combi F, Papi S, et al
    Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study.
    Anticancer Res. 2021;41:4535-4542.
    PubMed     Abstract available


  25. WANG YC, Wang ZH, Shen TC, Chang WS, et al
    Contribution of Interleukin-12A Genotypes to Breast Cancer Risk.
    Anticancer Res. 2021;41:4387-4393.
    PubMed     Abstract available


  26. LIAO CL, Peng SF, Chen JC, Chen PY, et al
    Allyl Isothiocyanate Induces DNA Damage and Impairs DNA Repair in Human Breast Cancer MCF-7 Cells.
    Anticancer Res. 2021;41:4343-4351.
    PubMed     Abstract available


  27. YONEMITSU K, Miyasato Y, Shiota T, Shinchi Y, et al
    Soluble Factors Involved in Cancer Cell-Macrophage Interaction Promote Breast Cancer Growth.
    Anticancer Res. 2021;41:4249-4258.
    PubMed     Abstract available


  28. WATANABE J, Nakamoto S, Sugino T
    The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution.
    Anticancer Res. 2021;41:4619-4627.
    PubMed     Abstract available


  29. RIFFEL J, Kannengiesser S, Schoenberg SO, Kaiser AK, et al
    T2-weighted Imaging of the Breast at 1.5T Using Simultaneous Multi-slice Acceleration.
    Anticancer Res. 2021;41:4423-4429.
    PubMed     Abstract available


    August 2021
  30. YAMADA M, Kubo M, Yamamoto H, Yamashita N, et al
    Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
    Anticancer Res. 2021;41:4143-4149.
    PubMed     Abstract available


  31. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy.
    Anticancer Res. 2021;41:4133-4141.
    PubMed     Abstract available


  32. OGINO M, Fujii T, Koibuchi Y, Nakazawa Y, et al
    Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.
    Anticancer Res. 2021;41:3899-3904.
    PubMed     Abstract available


  33. STELLER D, Simon R, VON Bialy R, Hakim SG, et al
    Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Anticancer Res. 2021;41:3917-3923.
    PubMed     Abstract available


  34. KIM H, Gim JA, Kim CY, Kim A, et al
    Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing.
    Anticancer Res. 2021;41:3779-3787.
    PubMed     Abstract available


    July 2021
  35. YAMANOUCHI K, Maeda S, Takei D, Koga Y, et al
    Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer.
    Anticancer Res. 2021;41:3625-3634.
    PubMed     Abstract available


  36. TANG A, Mooney CM, Beattie G, Cohan CM, et al
    Health Equity Within Inequity: Timing of Diagnostic Breast Cancer Care in an Underserved Medical Population.
    Anticancer Res. 2021;41:3607-3613.
    PubMed     Abstract available


  37. SUZUKI C, Yamada A, Adachi S, Shima H, et al
    Bromodomain-containing Protein 4 Is a Favourable Prognostic Factor in Breast Cancer Patients.
    Anticancer Res. 2021;41:3597-3606.
    PubMed     Abstract available


  38. RAJBONGSHI L, Noh MH, Kim YS, Hur DY, et al
    Effects of Epstein-Barr Virus Infection on the Response of Human Breast Cancer Cells to Nicotine.
    Anticancer Res. 2021;41:3449-3458.
    PubMed     Abstract available


  39. VIEIRA JF, Peixoto AP, Murta EFC, Michelin MA, et al
    Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases.
    Anticancer Res. 2021;41:3419-3427.
    PubMed     Abstract available


  40. KIM CY, Kim YC, Oh JH, Kim MH, et al
    HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
    Anticancer Res. 2021;41:3409-3417.
    PubMed     Abstract available


  41. MARCHICA P, D'Arpa S, Magno S, Rossi C, et al
    Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art.
    Anticancer Res. 2021;41:3233-3246.
    PubMed     Abstract available


    June 2021
  42. KIM K, Chun M, Jin H, Jung W, et al
    Inter-institutional Variation in Intensity-modulated Radiotherapy for Breast Cancer in Korea (KROG 19-01).
    Anticancer Res. 2021;41:3145-3152.
    PubMed     Abstract available


  43. AKAGI H, Shimada A, Chin K, Domoto H, et al
    Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient.
    Anticancer Res. 2021;41:3139-3144.
    PubMed     Abstract available


  44. MIKI M, Takao S, Konishi M, Shigeoka Y, et al
    Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
    Anticancer Res. 2021;41:3121-3126.
    PubMed     Abstract available


  45. KRAWCZYK N, Janowski K, Banys-Paluchowski M, Staebler A, et al
    The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2021;41:2849-2858.
    PubMed     Abstract available


  46. WALL TP, Crowley PD, Buggy DJ
    The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour In Vitro.
    Anticancer Res. 2021;41:2835-2840.
    PubMed     Abstract available


  47. OHLINGER R, Alwafai Z, Paepke S, Zygmunt M, et al
    Patient Quality of Life After Subpectoral Implant-based Breast Reconstruction With Synthetic or Biological Materials.
    Anticancer Res. 2021;41:3075-3082.
    PubMed     Abstract available


    May 2021
  48. ORSARIA P, Grasso A, Ippolito E, Pantano F, et al
    Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Anticancer Res. 2021;41:2697-2709.
    PubMed     Abstract available


  49. VANNI G, Pellicciaro M, Materazzo M, Pedini D, et al
    Advanced Stages and Increased Need for Adjuvant Treatments in Breast Cancer Patients: The Effect of the One-year COVID-19 Pandemic.
    Anticancer Res. 2021;41:2689-2696.
    PubMed     Abstract available


  50. RADES D, Narvaez CA, Dziggel L, Tvilsted S, et al
    Sleep Disorders in Patients With Breast Cancer Prior to a Course of Radiotherapy - Prevalence and Risk Factors.
    Anticancer Res. 2021;41:2489-2494.
    PubMed     Abstract available


  51. CHEN KY, Chien WC, Liao JM, Tsai CW, et al
    Contribution of Interleukin-10 Genotype to Triple Negative Breast Cancer Risk.
    Anticancer Res. 2021;41:2451-2457.
    PubMed     Abstract available


  52. ALAAELDIN R, Abuo-Rahma GEA, Zhao QL, Fathy M, et al
    Modulation of Apoptosis and Epithelial-Mesenchymal Transition E-cadherin/TGF-beta/Snail/TWIST Pathways by a New Ciprofloxacin Chalcone in Breast Cancer Cells.
    Anticancer Res. 2021;41:2383-2395.
    PubMed     Abstract available


  53. JINIH M, Wang JH, Pfirrmann RW, O'Leary DP, et al
    Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells.
    Anticancer Res. 2021;41:2247-2256.
    PubMed     Abstract available


  54. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available


    April 2021
  55. HAYASHI K, Tamura M, Nagasaki E, Yoshii Y, et al
    A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer.
    Anticancer Res. 2021;41:2193-2195.
    PubMed     Abstract available


  56. SASAKI R, Horimoto Y, Yanai Y, Kurisaki-Arakawa A, et al
    Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:2133-2140.
    PubMed     Abstract available


  57. VANNI G, Materazzo M, Pellicciaro M, Amir S, et al
    Breast Textured Implants Determine Early T-helper Impairment: BIAL2.20 Study.
    Anticancer Res. 2021;41:2123-2132.
    PubMed     Abstract available


  58. JOSEPH WJ, Bustos SS, Losee JE, Rubin JP, et al
    The Impact of the COVID-19 Pandemic on Breast Reconstruction Practices in the United States.
    Anticancer Res. 2021;41:1903-1908.
    PubMed     Abstract available


  59. RIGAKOS G, Razis E, Koliou GA, Oikonomopoulos G, et al
    Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
    Anticancer Res. 2021;41:1793-1802.
    PubMed     Abstract available


  60. OHLINGER R, Nawroth F, Kohlmann T, Alwafai Z, et al
    Retrospective Study of Radiotherapy Impact on the Outcome of Material-assisted Implant-based Subpectoral Breast Reconstruction.
    Anticancer Res. 2021;41:2017-2024.
    PubMed     Abstract available


  61. ZWICKER F, Hoefel S, Kirchner C, Huber PE, et al
    Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge.
    Anticancer Res. 2021;41:1909-1920.
    PubMed     Abstract available


    March 2021
  62. YAMAMOTO S, Narui K, Ishikawa T, Adachi S, et al
    First-line Gemcitabine Versus Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study.
    Anticancer Res. 2021;41:1671-1676.
    PubMed     Abstract available


  63. FERINI G, Molino L, Tripoli A, Valenti V, et al
    Anatomical Predictors of Dosimetric Advantages for Deep-inspiration-breath-hold 3D-conformal Radiotherapy Among Women With Left Breast Cancer.
    Anticancer Res. 2021;41:1529-1538.
    PubMed     Abstract available


  64. KRAJNAK S, Loewe A, Battista MJ, Hasenburg A, et al
    The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells.
    Anticancer Res. 2021;41:1243-1250.
    PubMed     Abstract available


  65. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available


    February 2021
  66. INOUE S, Kawaida H, Saito R, Nakayama Y, et al
    Clinical Significance of Past History of Breast Cancer Screening for the Prognosis of Triple Negative Breast Cancer.
    Anticancer Res. 2021;41:1077-1082.
    PubMed     Abstract available


  67. YAMADA A, Nakazawa K, Akazawa K, Narui K, et al
    Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study.
    Anticancer Res. 2021;41:1063-1068.
    PubMed     Abstract available


  68. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:949-954.
    PubMed     Abstract available


  69. OKAZAKI M, Mogushi K, Denda-Nagai K, Fujihira H, et al
    Biological and Clinicopathological Implications of Beta-3-N-acetylglucosaminyltransferase 8 in Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:845-858.
    PubMed     Abstract available


  70. RAICA M, Ceausu AR, Cimpean AM, ComSa S, et al
    Chloride Intracellular Channel Protein 1 (CLIC1), E-cadherin and P-cadherin Define Distinct Subclasses of HER2, Luminal B and Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:795-802.
    PubMed     Abstract available


  71. SHARIF-ASKARI FS, Al-Khayyal N, Talaat I, Sharif-Askari NS, et al
    Immunohistochemical Assessment of TNFAIP3/A20 Expression Correlates With Early Tumorigenesis in Breast Cancer.
    Anticancer Res. 2021;41:739-745.
    PubMed     Abstract available


  72. PAPADAKI MA, Aggouraki D, Vetsika EK, Xenidis N, et al
    Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Anticancer Res. 2021;41:661-670.
    PubMed     Abstract available


  73. UNGER J, Rutkowski R, Kohlmann T, Paepke S, et al
    Potential Risk Factors Influencing the Formation of Postoperative Seroma After Breast Surgery - A Prospective Study.
    Anticancer Res. 2021;41:859-867.
    PubMed     Abstract available


  74. WALKER RR, Gallegos KM, Bratton MR, Lemieux KP, et al
    Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade.
    Anticancer Res. 2021;41:583-599.
    PubMed     Abstract available


    January 2021
  75. SCHMIDT M, KUmmel S, Ruf-Doerdelmann A, Distelrath A, et al
    Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin((R))) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
    Anticancer Res. 2021;41:485-496.
    PubMed     Abstract available


  76. OBA T, Maeno K, Ono M, Ito T, et al
    Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
    Anticancer Res. 2021;41:445-452.
    PubMed     Abstract available


  77. SAGARA M, Miyamoto S, Itoh S, Soda Y, et al
    Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Anticancer Res. 2021;41:81-89.
    PubMed     Abstract available


  78. CHOI YE, Sung K, Dong KS, Kim HJ, et al
    Dosimetric Impact of Respiratory Motion During Breast Intensity-modulated Radiation Therapy Using Four-dimensional Dose Calculations.
    Anticancer Res. 2021;41:417-427.
    PubMed     Abstract available


  79. IBRAGIMOVA MK, Tsyganov MM, Pevzner AM, Litviakov NV, et al
    Transcriptome of Breast Tumors With Different Amplification Status of the Long Arm of Chromosome 8.
    Anticancer Res. 2021;41:187-195.
    PubMed     Abstract available


  80. ONAGA C, Tamori S, Motomura H, Ozaki A, et al
    High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers.
    Anticancer Res. 2021;41:43-54.
    PubMed     Abstract available


    December 2020
  81. VANNI G, Tazzioli G, Pellicciaro M, Materazzo M, et al
    Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients.
    Anticancer Res. 2020;40:7119-7125.
    PubMed     Abstract available


  82. MACAIONE I, Galvano A, Graceffa G, Lupo S, et al
    Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer.
    Anticancer Res. 2020;40:7083-7088.
    PubMed     Abstract available


  83. TSAI CL, Tsai CW, Chang WS, Su CH, et al
    Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility.
    Anticancer Res. 2020;40:6743-6749.
    PubMed     Abstract available


  84. YAMADA A, Suzuki C, Shima H, Kida K, et al
    Aldehyde Dehydrogenase 1-related Genes in Triple-negative Breast Cancer Investigated Using Network Analysis.
    Anticancer Res. 2020;40:6733-6742.
    PubMed     Abstract available


  85. NIWA Y, Asano M, Nakagawa T, France D, et al
    Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Anticancer Res. 2020;40:6699-6712.
    PubMed     Abstract available


  86. ANAYA-EUGENIO GD, Eggers NA, Ren Y, Rivera-ChAvez J, et al
    Apoptosis Induced by (+)-Betulin Through NF-kappaB Inhibition in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2020;40:6637-6647.
    PubMed     Abstract available


  87. ROBINSON AGJ, Kanaan YM, Copeland RL
    Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2020;40:6623-6635.
    PubMed     Abstract available


    November 2020
  88. NUZZO M, Ursini LA, Patani F, Rosa C, et al
    Using the Bolus in Post-mastectomy Radiation Therapy (PMRT): A National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Breast Cancer Group.
    Anticancer Res. 2020;40:6505-6511.
    PubMed     Abstract available


  89. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
    Anticancer Res. 2020;40:6417-6428.
    PubMed     Abstract available


  90. AUGUSTINE TN, Duarte R, Candy GP
    Breast Cancer Cells Induce a Pro-inflammatory Response to Mitigate Immune Mediation in a 3D Culture Model.
    Anticancer Res. 2020;40:6179-6193.
    PubMed     Abstract available


  91. SHIMODA M, Kim SJ, Tokuda Y, Sota Y, et al
    Effect of Computer-aided Detection System Use on the Duration of MRI-guided Biopsy of the Breast.
    Anticancer Res. 2020;40:6437-6441.
    PubMed     Abstract available


  92. STOPE MB, Benouahi R, Sander C, Haralambiev L, et al
    Protherapeutic Effects and Inactivation of Mammary Carcinoma Cells by a Medical Argon Plasma Device.
    Anticancer Res. 2020;40:6205-6212.
    PubMed     Abstract available


    October 2020
  93. SHINDEN Y, Nagata A, Nomoto Y, Saho H, et al
    Surgical Resection With Pedicled Rotation Flap for Post-mastectomy Locoregional Breast Cancer Recurrence.
    Anticancer Res. 2020;40:5739-5742.
    PubMed     Abstract available


  94. YENILMEZ EN, Genc D, Farooqi AA, Tunoglu S, et al
    Mesenchymal Stem Cells Combined With IFNgamma Induce Apoptosis of Breast Cancer Cells Partially Through TRAIL.
    Anticancer Res. 2020;40:5641-5647.
    PubMed     Abstract available


  95. MARGAN MM, Cimpean AM, Ceausu AR, Raica M, et al
    Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes.
    Anticancer Res. 2020;40:5557-5566.
    PubMed     Abstract available


  96. LI CL, Huang CW, Ko CJ, Fang SY, et al
    Curcumol Suppresses Triple-negative Breast Cancer Metastasis by Attenuating Anoikis Resistance via Inhibition of Skp2-mediated Transcriptional Addiction.
    Anticancer Res. 2020;40:5529-5538.
    PubMed     Abstract available


  97. SCATOZZA F, D'Amore A, Fontanella RA, DE Cesaris P, et al
    Toll-Iike Receptor-3 Activation Enhances Malignant Traits in Human Breast Cancer Cells Through Hypoxia-inducible Factor-1alpha.
    Anticancer Res. 2020;40:5379-5391.
    PubMed     Abstract available


  98. WAZIR U, Mokbel K
    De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
    Anticancer Res. 2020;40:5351-5354.
    PubMed     Abstract available


  99. KIM SW, Kim HS, Na K
    Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
    Anticancer Res. 2020;40:5925-5932.
    PubMed     Abstract available


  100. PARK JH, Ahn JH, Kim JE, Jung KH, et al
    Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Anticancer Res. 2020;40:5883-5893.
    PubMed     Abstract available


  101. YILDIRIM E, Bektas S, Gundogar O, Findik D, et al
    The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
    Anticancer Res. 2020;40:5649-5657.
    PubMed     Abstract available


  102. PERNICONE N, Peretz L, Grinshpon S, Listovsky T, et al
    MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis.
    Anticancer Res. 2020;40:5471-5480.
    PubMed     Abstract available


    September 2020
  103. NASIR UM, Mozeika AM, Sayan M, Jan I, et al
    Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.
    Anticancer Res. 2020;40:5291-5294.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: